Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 13;3(7):2213-2224.
doi: 10.3390/ph3072213.

High-Dose Ibuprofen in Cystic Fibrosis

Larry C Lands  1   2 , Nurlan Dauletbaev  3
Affiliations
Review

High-Dose Ibuprofen in Cystic Fibrosis

Larry C Lands et al. Pharmaceuticals (Basel). .

Abstract

Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.

Keywords: CFTR; cystic fibrosis; ibuprofen; interleukin-8; neutrophils.

PubMed Disclaimer

References

    1. Anselmo M., Lands L. Cystic Fibrosis: Overview. In: Taussig L., Landau L., editors. Pediatric Respiratory Medicine. 2nd. Mosby; Philadelphia, PA, USA: 2008. pp. 845–857.
    1. Claustres M., Guittard C., Bozon D., Chevalier F., Verlingue C., Ferec C., Girodon E., Cazeneuve C., Bienvenu T., Lalau G., Dumur V., Feldmann D., Bieth E., Blayau M., Clavel C., Creveaux I., Malinge M.C., Monnier N., Malzac P., Mittre H., Chomel J.C., Bonnefont J.P., Iron A., Chery M., Georges M.D. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum. Mutat. 2000;16:143–156. - PubMed
    1. Muhlebach M.S., Stewart P.W., Leigh M.W., Noah T.L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am. J. Respir. Crit. Care Med. 1999;160:186–191. - PubMed
    1. Farrell P.M., Collins J., Broderick L.S., Rock M.J., Li Z., Kosorok M.R., Laxova A., Gershan W.M., Brody A.S. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology. 2009;252:534–543. - PMC - PubMed
    1. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., Stokes D.C., Wohl M.E., Wagener J.S., Regelmann W.E., Johnson C.A. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J. Pediatr. 2007;151:134–139. doi: 10.1016/j.jpeds.2007.03.006. - DOI - PubMed

LinkOut - more resources